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Abstract
Background: Women infected with human immunodeficiency virus (HIV) may be at higher risk
of developing cervical cancer than non infected women. In a pilot study, we assessed the
relationships among cervical cytology abnormalities associated to Human Papillomavirus (HPV),
HIV infection and Highly Active Antiretroviral Therapy (HAART) on the development of Squamous
Intraepithelial lesions (SILs). Out of the 70 HIV infected women from Douala -Cameroon (Central
Africa) that we included in the study, half (35) were under HAART. After obtaining information
related to their lifestyle and sexual behaviour, cervicovaginal samples for Pap smears and venous
blood for CD4 count were collected and further divided into two groups based upon the presence
or absence of cervical cytology abnormalities i.e. those with normal cervical cytology and those
with low and high Squamous Intraepithelial lesions (LSIL, HSIL).
Results: Assessment was done according to current antiretroviral regimens available nationwide
and CD4 count. It was revealed that 44.3% of HIV-infected women had normal cytology. The
overall prevalence of LSIL and HSIL associated to HPV in the studied groups was 24.3% (17/70) and
31.4% (22/70) respectively. Among the 22 HSIL-positive women, 63.6% (14/22) were not on
antiretroviral therapy, while 36.4% (8/22) were under HAART. HIV infected women under HAART
with positive HSIL, showed a median CD4+ T cell count of 253.7 +/- 31.7 higher than those without
therapy (164.7 +/- 26.1). The incidence of HSIL related to HPV infection within the study group
independently of HAART initiation was high.
Conclusion: These results suggest the need for extension and expansion of the current study in
order to evaluate the incidence of HPV infection and cervical cancer among HIV-infected and non
HIV- infected women in Cameroon.
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Background
Genital infection by human papillomavirus (HPV) is one
of the most common sexually transmitted infections,
known to be the cause of cervical cancer [1-3]. Although
HPV is known to be strongly associated with the develop-
ment of cervical cancer, most HPV infections in young
women are transient [4]. Women with persistent infection
appear to have a higher risk of developing significant cer-
vical cancer [2,5]. The burden of this infection on public
health is compounded by the recognized causal relations
between genital HPV infection and cervical dysplasia or
cervical cancer [6,7]. Although factors that influence per-
sistence of HPV are not yet well understood, several stud-
ies suggest that alterations in cell mediated immune
responses play a major role in persistence of HPV. The
higher rates of HPV infection, high-grade squamous
intraepithelial lesion (HSIL), and cervical cancer among
immunosuppressed individuals, specifically HIV-infected
women, underscore the importance of control of immune
response in HPV infection. Studies on adult women have
consistently shown that the prevalence of HPV infection
and HSIL are higher among HIV infected women and that
these differences are exaggerated among women with
lower CD4+ cell counts [8-10]. Several recent prospective
studies have documented that the rate of persistence of
HPV among HIV-infected women is higher than that
among non HIV-infected women [11,12]. Specific types
of HPV are associated with cervical cancer, but whether
these high-risk types have natural histories that are differ-
ent from those of other types not associated with cervical
cancer is unknown [13,14]. The modification of the viral
markers may be the crucial factor of disequilibrium in the
interaction between virus and host: an increased replicat-
ing capacity of the virus versus a reduced control mecha-
nism of the immune system. In this context it's evident
that in HIV-infected women, both viral and host factors
conspire, as these patients have an impaired immune sys-
tem usually more exposed to HPV infection. Some studies
have also considered the impact on cervical pathology on
HIV disease care, mainly represented by the introduction
of highly active antiretroviral therapy (HAART), which
through the substantial recovery of immune function has
significantly changed the scenario regarding HIV-related
pathologies such as opportunistic infections and cancers
[15,16]. The objectives of this study were to compare rates
of cervical abnormalities related to HPV infection among
HIV-infected women with and without HAART initiation
and to examine immunological and behavioural risk fac-
tors associated with persistence of HPV.
Subjects and methods
Study population
A total of 70 HIV-infected women were enrolled in the
study after informed consent and divided into two groups:
35 under HAART and 35 not initiated with HAART.
Within eight (08) month, patients aged between 21–56
years, were recruited in a day care centre at Bonassama
hospital in Douala for HIV therapy. All were included in a
pilot study on clinical and behavioural characteristics
associated with HIV infection. The study was carried out
according to the guidelines for human experimental mod-
els in clinical research as stated by the ministry of public
Health of Cameroon.
Inclusion criteria
Enrolled women were single or married; non-pregnant;
aged 21 years old and above and HIV infected, initiated or
not with HAART. Patients were divided in two groups:
group one consisted of women who were diagnosed HIV
positive and were not yet eligible for antiretroviral ther-
apy. Patients in this group were considered untreated only
at the beginning of the study. The second group com-
prised HIV-infected women receiving HAART, who were
enrolled on the basis of a three months' minimum length
of treatment. Patients in this group had different thera-
peutic protocols spread over different periods of treat-
ment. From the list of patients eligible for the study,
subjects were randomly chosen in a systematic manner.
The objective of the study was explained to patients and
verbal consent was sought from each of them.
Collection of Specimens
At the screening visit, venous blood was collected for CD4
analysis, and pap smears performed for early detection of
cervical carcinoma as previously described [17]. Subjects
underwent a general physical examination and completed
a short standardized interview, including questions per-
taining to medical history, sexual behaviour, history of
STIs, age of first sexual intercourse, pregnancy, parity and
abortion.
Histological analysis
Pap smears were interpreted and classified according to
the Bethesda System as negative, atypical squamous cells
of unknown significance, LSIL, HSIL, or invasive cervical
cancer [18,19]. Conventional Pap smears were used and
slides were read by a pathologist. Blood samples were
obtained for flow cytometry CD4+ T cell counts using
AIDS Clinical Trials Group standardized flow-cytometry
protocols as described elsewhere [20].
Statistical analysis
Data obtained were verified for consistency, coded, and
computerized. Throughout the text, values are given as
mean ± s.d. Percentages were calculated from the overall
number of cases. Raw data were compared using Fisher's
exact-test (StatXact 2.05 software). Appropriate probabili-
ties were calculated [21] and size variation with Mann-
Whitney rank sum test as the normality test failed (Sigma
Stat 2.03 software).Infectious Agents and Cancer 2009, 4:9 http://www.infectagentscancer.com/content/4/1/9
Page 3 of 7
(page number not for citation purposes)
Results
Subjects characteristics
Seventy HIV infected women were randomly recruited
using systemic random sampling from the outpatients at
the day care centre of Bonassama hospital in Douala.
Table 1 summarizes the socio-demographic information
as well as information on reproductive and sexual charac-
teristics of the study groups. Sampling was done according
to: age with a mean age of 35.5 ± 1.9 years and 35.1 ± 1.3
years; age of first vaginal sex with a mean age of 16.9 ± 5
years and 17.2 ± 0.5 years; number of pregnancies with a
mean number of 3.7 ± 0.5 and 3.9 ± 0.4; parity with a
mean number of 2.6 ± 0.5 and 2.6 ± 0.4; abortion with a
mean number of 1.2 ± 0.2 respectively for women under
HAART and women not initiated with HAART. Significant
differences were observed between these groups at base-
line in terms of ages of patients: when comparing the
mean age of patients above 40 years (52.3 ± 2.3% (9) vs.
44.9 ± 1.2% (10), P = 0.007) and when comparing the
mean parity of more than 4 (9.8 ± 0.7% (4) vs. 5.9 ± 0.5%
(8), P = 0.006) for treated and untreated group respec-
tively. The significant difference observed between treated
and untreated groups in terms of mean age and parity is
probably due to the number patients assigned to each
parameter.
HAART and incidence of cervical abnormalities
Table 2 presents histological analyses of studied samples.
The Pap smear test results revealed the following within
the study groups: those with normal cervical cytology
(44.3%) and those with abnormal Pap smear; LSIL
(24.3%), and HSIL (31.4%) respectively. The cervical
abnormalities differences were statistically significant for
the two study groups when comparing the total frequency
abnormalities (48.6% vs. 62.9%, P = 0.034) for treated
and untreated groups respectively. Table 3 represents the
frequency of distribution of cervical cytology results in the
treated and untreated groups according to the duration of
therapy. Cervical abnormalities are high in the absence of
therapy: 47.1% and 63.6% for LSIL and HSIL respectively.
The difference in the distribution of the cytological picture
among LSIL and HSIL cases was statistically none signifi-
cant (P > 0.05). Table 4 represents the Incidence of cervi-
cal cytology results in the HAART treatment group
according to the duration of therapy. Normal cervical
cytology increase with the duration of therapy: 5.7% to
34.3% within the period of treatment 1–5 month and
Table 1: Selected baseline characteristics of HIV infected women as study subjects.
Under HAART No HAART
Groups n% M e a n  ±  S E a n % Mean ± SE p value
A. Age (years)
<30 12 34.3 26.4 ± 0.7 10 28.6 26.4 ± 0.9 0.988 ns
30 – 40 14 40.0 32.4 ± 0.8 15 42.8 34.3 ± 0.9 0.115 ns
>40 9 25.7 52.3 ± 2.3 10 28.6 44.9 ± 1.2 0.007 *
Total 35 - 35.5 ± 1.9 35 - 35.1 ± 1.3 0.872 ns
B. Age at first vaginal sex (years)
≤ 16 18 51.4 14.6 ± 0.3 15 42.9 14.5 ± 0.3 0.874 ns
>16 17 48.6 19.3 ± 0.7 20 57.1 19.3 ± 0.4 0.956 ns
Total 35 - 16.9 ± 0.5 35 - 17.2 ± 0.5 0.643 ns
C. Pregnancy
0 2 5.7 0.0 ± 0.0 0 0.0 0.0 ± 0.0 -
1 – 4 23 65.7 2.3 ± 0.3 22 62.9 2.3 ± 0.2 0.971 ns
5 – 9 7 20.0 6.1 ± 0.6 11 31.4 5.9 ± 0.4 0.750 ns
>10 3 8.6 11.0 ± 0.6 2 5.71 10.5 ± 0.5 0.800 ns#
Total 35 - 3.7 ± 0.5 35 - 3.9 ± 0.4 0.737 ns
D. Parity
0 7 20.0 0.0 ± 0.0 5 14.3 0.0 ± 0.0 -
1 – 4 24 68.6 2.1 ± 0.3 22 62.8 2.0 ± 0.2 0.711 ns
>4 4 11.4 9.8 ± 0.7 8 22.8 5.9 ± 0.5 0.006 *
Total 35 - 2.6 ± 0.5 35 - 2.6 ± 0.4 0.964 ns
E. Abortion
0 13 37.1 0.0 ± 0.0 12 34.3 0.0 ± 0.0 -
1 – 2 15 42.9 1.2 ± 0.1 17 48.6 1.4 ± 0.1 0.353 ns
>2 7 20.0 3.4 ± 0.2 6 17.1 3.3 ± 0.3 0.628 ns
Total 35 - 1.2 ± 0.2 35 - 1.2 ± 0.2 0.925 ns
a. Means were compared one after the other using the Student t-test when normality and equal variance conditions passed or the Mann-Whitney 
rank sum test when conditions failed.
Ns: no significant difference; * significant difference; #: Mann-Whitney rank sum testInfectious Agents and Cancer 2009, 4:9 http://www.infectagentscancer.com/content/4/1/9
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more than 10 month respectively. Within the same
period, HSIL decreased from 14.3% to 2.8% and was
probably due to the number of patients within the more
than 10 months' period of therapy. The difference in the
incidence of cervical abnormalities was statistically non
significant (P = 0.069). Table 5 represents CD4+ T cell
count distribution within the study groups according to
cervical abnormalities. The mean of CD4+ T cell count
decreases with degree of cervical abnormalities in both
groups: 289 ± 47.0, 253 ± 69.1 and 173.4 ± 42.4 T cells in
patients under HAART while those with no HAART initia-
tion have 244.5 ± 42.8, 218.4 ± 64.1 and 59.9 ± 14.5 for
normal, LSIL and HSIL respectively. Table 6 examines
some of the risk factors that might contribute to HPV
infection. The risk factors investigated were grouped
according to the following parameters of personal history:
age of first vaginal sex, pregnancy and abortion. The
results showed that patients with cervical abnormalities
were mainly ≥ 19 years old at first vaginal sex intercourse
with high percentage: 23.5% and 20.2% for LSIL and HSIL
respectively. There was no statistical difference for this fac-
tor when compared with Mann-Whitney test. Reproduc-
tive history of the studied groups showed a statistically
non significant difference between the LSIL and HSIL pos-
itive patients neither for pregnancy nor for abortion. In
patients with the highest percentage for pregnancies, i.e. ≤
10 pregnancies we noticed 76.4% and 45.5% occurrence
for LSIL and HSIL respectively while for abortion, the
cytology results findings showed 70.6% and 36.4% for
LSIL and HSIL respectively in patients with 1 or more than
2 abortions. Table 7 represents distribution of STI risk fac-
tors that might contribute to HPV infection. The history of
STIs risk factors shows that: Bacillus vaginalis, Chlamydia sp
and  Treponema Pallidum are main microbial infectious
agents. B. vaginalis is the leading infection with 70.6% and
54.5% for LSIL and HSIL respectively while Chlamydia is
the second with 17.6% and 22.7% and T. Pallidum which
count for 5.9% and 13.6% respectively for LSIL and HSIL
positives patients. No significant statistical difference was
found in correlation with cervical abnormalities.
Discussion
This study provides data on the risk of cervical cancer
among HIV positive women less than 60 years old in the
day care centre at Bonassama hospital Douala -Central
Africa. The extent to which HIV increases the risk for cer-
vical cancer is especially important in Cameroon referring
to the epidemiology of the HIV especially among women.
In our study, HIV positive women are at high risk of inva-
sive cervical cancer. This could be due to the competing
risk of mortality from other conditions associated with
Table 2: Frequency of cervical abnormalities in HIV infected women according to cytological findings
Under HAART(35) No HAART (35) Total (70) p-value
Groups n% n % n %
Normal 18 51.4 13 37.1 31 44.3
LSILa 9 25.7 8 22.9 17 24.3
HSILb 8 22.9 14 40.0 22 31.4
Total abnormalities 17 48.6 22 62.9 39 55.7 0.034*
a. Low squamous intra epithelial lesions b. High squamous intra epithelial lesions
* Significant difference
Table 3: Frequency of cervical abnormalities in HIV infected 
women according to duration of medication (HAART)
Duration Cervical abnormalitya
(month) LSIL HSIL
n % n % Exact p-valueb
0 08 47.1 14 63.6 0.1308 ns
1–5 03 17.7 05 22.7 0.6193 ns
6–10 02 11.8 02 09.1 1.000 ns
> 10 04 23.5 01 04.5 0.2063 ns
Total 17 - 22 - 0.3652 ns
a. Combined data for treated and untreated patients
b. Global comparison of raw data: Pearson's chi-square exact 
probability: P = 0.3725)
Table 4: Cervical abnormalities incidence in HIV infected women 
under HAART therapy according to and duration of medication
Duration Normal LSIL HSIL
( m o n t h ) n %n%n%
0 - -----
1–5 2 5.7 3 8.6 5 14.3
6–10 4 11.4 2 5.7 2 5.7
> 10 12 34.3 4 11.4 1 2.8
Total 18 51.4 9 25.7 8 22.8
a. exact probability using Pearson's Chi-square test for independence 
procedure: P = 0.069Infectious Agents and Cancer 2009, 4:9 http://www.infectagentscancer.com/content/4/1/9
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HIV/AIDS, particularly in a setting where antiretroviral
therapy was not available at the time and for all patients.
Our findings that HIV infected women were at a signifi-
cantly higher risk of LSIL and HSIL confirm the results of
studies carried out in both developed and other develop-
ing countries [7,17,22-24]. The relative prevalence of SILs
or cytological abnormalities among HIV positive women
is higher than that ever been reported by any other study
in Africa. Hawes et al. reported a cytological abnormality
prevalence of 37% among women with HIV-1 infection
attending an outpatients infectious disease clinic in Sen-
egal [17], Yamada 27.1% in urban patients in Kenya [25],
Moukassa 15.36% among urban dwellers in Congo [26].
A potential limitation of this current study is that cytolog-
ical abnormalities were not histologically confirmed.
However, it has been shown that the Pap smear sensitivity
and specificity are similar among HIV negative and HIV
positive women [27]. We found an association between
HAART and the stage of cervical pre-cancer. Our results are
in agreement with others that have shown an association
between HIV, HAART and cervical abnormalities [[15,16],
and [28]]. An additional limitation of our study is that
complete information regarding the immunological sta-
tus of patients has not been documented for all the
groups. Similar of different studies by the same author
[[9,15,16,20,25], and [29]] have reported that the severity
of HIV-related immunodepression is associated with
increased incidence of HPV infection and SILs. Data
obtained from the current study further confirm these
findings reported by other investigators of our geographic
area [17,22-26]. Several studies suggested that markers of
advanced HIV disease such as CD4+ T cell counts or HIV-
RNA plasmatic levels are associated with increased risk of
HPV infection and SIL [8,17,28,29]. However some docu-
mentations and data have revealed that the relationship
between HIV and HPV is more complex. Human immun-
odeficiency virus infection is associated with an increased
transcriptional activity of early HPV genes. Studies on
adult women have shown that HPV infection with both
high-risk and low-risk HPV types is more likely to persist
among HIV-infected women [8,12]. Because they have
more years of sexual activity, adult women may reflect a
group of women further along in their history of HIV and
HPV infection. Our data further support the important
role played by CD4+ T cells [28,29] in the control of HPV
Table 5: CD4+ T cell count distribution in HIV infected women 
according to cervical abnormalities
Under HAART No HAART
Groups n% M e a n  ±  S En% M e a n  ±  S E
Normal 18 51.4 289.4 ± 47.0 13 37.1 244.5 ± 42.8
LSIL 9 25.7 253.6 ± 69.1 8 22.9 218.4 ± 64.1
HSIL 8 22.9 173.4 ± 42.4 14 40.0 59.9 ± 14.5
Total 35 - 253.7 ± 31.7 35 - 164.7 ± 26.1
Table 6: Incidence of risk factors on cervical disease in HIV infected women under treatment (HAART) and those without treatment 
or HAART initiation
LSIL HSIL Mann-Withney test
Groups n% M e a n  ±  S E n% M e a n  ±  S E
Age at first vaginal sex (years)
<15 03 17.6 13.7 ± 0.3 06 27.3 13.2 ± 0.3 0.381 ns
15 – 18 10 58.8 16.5 ± 0.5 11 50.0 16.4 ± 0.3 0.860 ns
≥ 19 04 23.5 19.8 ± 0.5 05 22.7 20.2 ± 0.7 0.905 ns
Total 17 - 16.8 ± 0.5 22 - 16.4 ± 0.6 0.571 ns
Pregnancy
≤ 4 13 76.4 2.4 ± 0.3 10 45.5 2.8 ± 0.3 0.420 ns
5–9 02 11.8 5.5 ± 0.5 10 45.5 1.4 ± 0.4 0.590 ns
≥ 10 02 11.8 11.5 ± 0.5 02 09.0 0.7 ± 0.5 0.333 ns
Total 17 - 3.8 ± 0.8 22 - 5.1 ± 0.6 0.068 ns
Abortion
0 03 17.6 0.0 ± 0.0 06 27.3 0.0 ± 0.0 -
1–2 12 70.6 1.3 ± 0.3 08 36.4 1.4 ± 0.2 0.669 ns
> 2 02 11.7 3.0 ± 0.0 08 36.4 3.6 ± 0.3 0.400 ns
Total 17 - 1.24 ± 0.2 22 - 1.8 ± 0.3 0.372 nsInfectious Agents and Cancer 2009, 4:9 http://www.infectagentscancer.com/content/4/1/9
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infection: the lower the CD4+ T cell count, the more likely
that HPV infection will persist. Persistent infection in turn
may increase the risk for the development and persistence
of squamous intraepithelial lesions. In fact, women
whose immunosuppression is related to infection with
human immunodeficiency virus are at increased risk of
infection with multiple types of HPV [28]. In developed
countries it's recommended for HIV positive women to
have two cervical cytological assessments within the first
year after HIV diagnosis and annually thereafter, referred
for colposcopy for any smear showing an ASCUS (atypical
squamous cells of undetermined significance) or more
severe lesions [30]. These guidelines are not feasible in set-
tings with limited or poor resources. The high prevalence
and risk of cervical abnormalities documented in our
research projet underscores the importance of developing
screening and management guidelines for HIV positive
women. As antiretroviral therapy becomes increasingly
available in Cameroon, the life expectancy of HIV positive
women will increase as well. It's therefore important to
conserve this invaluable benefit and avoid its upset by an
increased risk in the development of cervical cancer. A cer-
vical screening program is of critical importance as it
informs local researchers on the natural history of cervical
abnormalities, which might be recommended for HIV
positive women. The STIs history of studied subjects
revealed the presence of reproductive tract infection in
patients with cervical cytology abnormality. This high rate
of infection is attributed to the promiscuous sexual behav-
iour of the sampled women. Other studies suggest lack of
hygiene, crowded or unsanitary living conditions, stress,
and the presence of other sexually transmitted infections
as factors that spread HPV infection and, eventually cervi-
cal cancer [30]. In the current study, history of STI infec-
tions was a non significant risk predictor in distinguishing
LSIL to HSIL positive cases.
Conclusion
HPV infection increased in accordance with lower CD4+ T
cell counts and higher HIV RNA levels. High-grade lesions
were strongly associated with high-risk HPV infection and
low CD4+ T cell counts. Immunodeficiency as a result of
HIV infection appears to be important for malignant pro-
gression within the cervix. Nationwide prevention of HIV
infection and cervical cancer screening are necessary for
the health of women in Cameroon. The increased public
health burden enhanced by HPV is an important and gen-
der-specific aspect of HIV infection. Guidelines on proper
screening for cervical abnormalities in HIV positive
women are urgently needed in Cameroon.
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